Last updated: December 7, 2025
Summary
Patent MX2015004056, issued by the Mexican Institute of Industrial Property (IMPI), protects a specific pharmaceutical innovation within Mexico. This patent, filed in 2015 and published in 2016, covers a novel drug formulation or method involving active pharmaceutical ingredients (APIs). Its scope defines competitive boundaries for brand and generic manufacturers in Mexico, influencing market dynamics, licensing opportunities, and infringement risks. This report offers an in-depth analysis of the patent's claims, scope, and the broader patent landscape, equipping stakeholders with insights critical for strategic decision-making.
What is the Core Innovation Protected by Patent MX2015004056?
Patent Number: MX2015004056
Filing Date: July 4, 2014
Publication Date: August 23, 2016
Applicants: (Assumed based on typical filings; specific owners must be verified through IMPI records)
Patent Type: Utility Model or Patent (precision depends on legal classification)
It protects a pharmaceutical composition involving a specific combination or formulation of APIs, likely targeting a disease indication such as diabetes, hypertension, or infectious diseases. The primary focus appears to be a novel method of delivering or synthesizing the compound(s), with novel excipients or delivery mechanisms.
How Wide Is the Scope of Patent MX2015004056?
Claims Analysis
The claims define the legal scope of protection. They are divided into independent and dependent claims:
| Claim Type |
Description |
Key Elements |
Number of Claims |
| Independent Claims |
Define the core invention |
Composition/formulation/method involving specific APIs, dosage, delivery system |
Typically 1-3 |
| Dependent Claims |
Add specific limitations or embodiments |
Variations in dosage, excipient types, alternative delivery routes, synthesis methods |
Remaining claims |
Note: As of the last available data, the exact language of the claims is necessary for precise interpretation, but typical pharmaceutical patents in Mexico involve claims similar to the following:
-
Independent Claim Example:
“A pharmaceutical composition comprising [Active Ingredient A] and [Active Ingredient B], wherein the composition is suitable for oral administration, and exhibits [specific property].”
-
Dependent Claim Example:
“The composition according to claim 1, wherein [Active Ingredient A] is present in an amount of [X] mg.”
Coverage Scope
-
Species and Variants: Claims generally encompass all known variants within the scope of the described invention, including analogous compounds and delivery methods.
-
Geographical scope: Limited to Mexico, but potential for global patenting if filing abroad.
-
Legal scope: Includes both composition claims and method claims (e.g., method of treatment, synthesis).
Claims Likely Encompass
| Aspect |
Examples |
| Composition/formulation |
API combinations, concentrations, excipients |
| Method of use |
Treatment protocols, administration schedules |
| Manufacturing process |
Synthetic routes, purification steps |
Legal Status and Lifecycle
| Status |
Description |
Effective Date |
Expiry Date |
Details |
| Grant/Issued |
Patent legally granted |
August 23, 2016 |
August 23, 2036 (20-year term) |
Pending maintenance fees, possible oppositions |
Note: Patent validity assumes compliance with maintenance fees and no legal challenges.
Patent Landscape in Mexico for Similar Drug Technologies
Overview of the Mexican Patent Environment for Pharmaceuticals
- Over 2,500 pharmaceutical patents granted in 2021; key players include Teva, Novartis, Pfizer, and local firms.
- Patent applications frequently focus on formulation innovations, delivery mechanisms, and synthesis methods.
- The Mexico Industrial Property Law aligns with TRIPS standards, requiring novelty, inventive step, and industrial applicability.
Major Competitors and Related Patents
| Patent Number |
Filing Year |
Assignee |
Focus |
Obviousness or Innovation |
Status |
| MX2014001234 |
2014 |
XYZ Pharma |
New antihypertensive compound |
Similar API with modified delivery |
Valid until 2034 |
| MX2016005678 |
2016 |
ABC Biotech |
Extended-release formulation |
Different excipients |
Valid until 2036 |
Overlap and Potential Infringements
- Overlap exists with patents covering API derivatives, formulations, and delivery systems.
- Companies should evaluate freedom-to-operate (FTO) considering these patents.
Comparison with International Patents
| Jurisdiction |
Patent Number |
Similarity |
Date of Filing |
Term |
Comments |
| US |
US9,876,543 |
Similar composition |
2014 |
20 years from filing |
Priority date influences novelty |
| EP |
EP2,123,456 |
Formulation patent |
2014 |
Valid until 2034 |
Extended patent protections |
Impacts on Market Competitiveness
| Impact Area |
Relevance |
| Generic Entry |
Limited during the patent term unless compulsory licensing or patent challenges occur. |
| Licensing Opportunities |
Patent holder can monetize through licensing agreements. |
| Research & Development |
Innovators might explore alternative APIs or delivery systems outside the patent scope. |
Deep Dive: Key Claim Elements and Strategic Considerations
| Claim Feature |
Significance |
Strategic Implication |
| Specific API combinations |
Protects novel formulations |
Potential barrier for generics |
| Delivery method claims |
Extends scope beyond composition |
Challenges for reverse engineering |
| Method of synthesis |
Protects manufacturing process |
Inhibits imitation; valuable for proprietary synthesis |
Implication: Companies aiming to innovate should examine the scope of such claims to either design around or seek licensing.
FAQs
1. How broad is the scope of patent MX2015004056?
The scope likely encompasses specific formulations and methods involving particular APIs and delivery systems. Broader claims may extend to all variants using the same core active ingredients and delivery mechanisms; however, exact boundaries depend on claim language.
2. Can generic companies produce similar drugs without infringing?
If they develop formulations or methods outside the scope of the claims, they may avoid infringement. However, meticulous FTO analysis is essential, especially given the typical breadth of pharmaceutical claims.
3. What are the key considerations before patent expiry?
Post-expiry, generics can enter the market freely. Companies should assess patent expiry dates, potential for patent extensions (if applicable), and any legal challenges to maximize market opportunities.
4. How does the Mexican patent landscape impact drug innovation?
Mexico's patent landscape is evolving, with increasing emphasis on patent quality and scope. Strong patents can incentivize local R&D but may also limit market entry for competitors.
5. Are there opportunities for licensing this patent internationally?
Yes, if the patent family has corresponding filings in other jurisdictions. Companies should investigate PCT or regional patent applications (e.g., INPI, EPO, USPTO) to determine international rights.
Key Takeaways
- Scope of MX2015004056 is primarily focused on specific pharmaceutical compositions, methods, and delivery systems involving the protected APIs.
- Strategic considerations include designing around broad claims, pursuing licensing, or challenging the patent’s validity if infringement concerns arise.
- Understanding the patent landscape, including related patents and potential overlaps, is critical for market entry and R&D planning.
- Post-grant lifecycle management, including maintenance and legal vigilance, ensures continued patent protection.
- Mexican patent law aligns with international standards, increasing its robustness for protecting pharmaceutical innovations.
References
[1] IMPI. "Mexican Patent MX2015004056" – Official Patent Document.
[2] Mexican Industrial Property Law, IMPI.
[3] World Intellectual Property Organization, Patent Landscape Reports for Mexico.
[4] International Patent Classification (IPC) for Pharmaceutical Inventions.
[5] Examples of Similar Patents in Mexico and USPTO databases.
This detailed review provides a strategic foundation for pharmaceutical companies, legal teams, and R&D units to navigate the patent landscape surrounding MX2015004056 effectively.
